NAS:ARWR (USA)
Business Description
Arrowhead Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Compare
Compare
Traded in other countries / regions
HDP1.Germany
•
ARWR.Mexico
•
0HI3.UK
•
ARWR.USA
Description
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.14 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -0.54 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 9.59 | |||||
| Beneish M-Score | -2.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 90.4 | |||||
| 3-Year EBITDA Growth Rate | -30.3 | |||||
| 3-Year EPS without NRI Growth Rate | -27.9 | |||||
| 3-Year Book Growth Rate | 53.6 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.91 | |||||
| 9-Day RSI | 63.81 | |||||
| 14-Day RSI | 62.87 | |||||
| 6-1 Month Momentum % | -18.07 | |||||
| 12-1 Month Momentum % | -30.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.37 | |||||
| Quick Ratio | 3.37 | |||||
| Cash Ratio | 3.25 | |||||
| Days Sales Outstanding | 3.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.6 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -63.84 | |||||
| Net Margin % | -61.59 | |||||
| ROE % | -36.23 | |||||
| ROA % | -21.75 | |||||
| ROIC % | -39.79 | |||||
| ROC (Joel Greenblatt) % | -192.93 | |||||
| ROCE % | -28.57 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 20.19 | |||||
| PB Ratio | 11.02 | |||||
| Price-to-Tangible-Book | 11.34 | |||||
| EV-to-EBIT | -29.27 | |||||
| EV-to-Forward-EBIT | -40.22 | |||||
| EV-to-EBITDA | -31.28 | |||||
| EV-to-Forward-EBITDA | -53.22 | |||||
| EV-to-Revenue | 18.69 | |||||
| EV-to-Forward-Revenue | 13.46 | |||||
| EV-to-FCF | -38.97 | |||||
| Price-to-Projected-FCF | 13.71 | |||||
| Price-to-Median-PS-Value | 0.24 | |||||
| Price-to-Net-Current-Asset-Value | 37.24 | |||||
| Price-to-Net-Cash | 42.22 | |||||
| Earnings Yield (Greenblatt) % | -3.42 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:ARWR
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 249.939 | ||
| EPS (TTM) ($) | -1.48 | ||
| Beta | 1.18 | ||
| Volatility % | 43.12 | ||
| 14-Day RSI | 62.87 | ||
| 14-Day ATR ($) | 2.388272 | ||
| 20-Day SMA ($) | 44.093 | ||
| 12-1 Month Momentum % | -30.59 | ||
| 52-Week Range ($) | 26.81 - 84.83 | ||
| Shares Outstanding (Mil) | 105.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arrowhead Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||